BofA Global Research raised AstraZeneca's 2025 EPS forecast to $9.07, up from $8.96. They expect 1Q25 revenue of $14 billion, an 11% year-over-year rise.
AstraZeneca and Daiichi Sankyo gained EU approval for Enhertu, a treatment for advanced hormone receptor-positive HER2-low breast cancer, based on the Destiny-Breast06 phase 3 trial results.
AstraZeneca's Imfinzi regimen, combined with chemotherapy, has been approved by the European Commission for treating adults with high-risk resectable non-small cell lung cancer.
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.